Obinutuzumab

Generic Name
Obinutuzumab
Brand Names
Gazyva, Gazyvaro
Drug Type
Biotech
Chemical Formula
-
CAS Number
949142-50-1
Unique Ingredient Identifier
O43472U9X8
Background

Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Le...

Indication

Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.

Associated Conditions
Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
Associated Therapies
-

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

First Posted Date
2017-10-16
Last Posted Date
2024-10-24
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
21
Registration Number
NCT03311126
Locations
🇺🇸

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

First Posted Date
2017-09-08
Last Posted Date
2023-01-10
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
136
Registration Number
NCT03276468
Locations
🇫🇷

CHU de Caen, Caen, France

🇫🇷

CHRU de Lille, Lille, France

🇫🇷

CHU d'Angers, Angers, France

and more 22 locations

Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2017-07-25
Last Posted Date
2023-08-16
Lead Sponsor
Polish Lymphoma Research Group
Target Recruit Count
1
Registration Number
NCT03229382
Locations
🇵🇱

Centrum Onkologii - Instytut im. Marii Skłodowskiej- Curie Klinika Nowotworów Układu Chłonnego, Warszawa, Poland

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

First Posted Date
2017-07-21
Last Posted Date
2024-12-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
145
Registration Number
NCT03223610
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

First Posted Date
2017-06-26
Last Posted Date
2024-06-11
Lead Sponsor
AstraZeneca
Target Recruit Count
35
Registration Number
NCT03198650
Locations
🇯🇵

Research Site, Suita-shi, Japan

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2017-05-09
Last Posted Date
2023-06-01
Lead Sponsor
Northwell Health
Target Recruit Count
3
Registration Number
NCT03145480
Locations
🇺🇸

Northwell Health/CLL Research and Treatment Program, New Hyde Park, New York, United States

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

First Posted Date
2017-05-01
Last Posted Date
2021-12-07
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
29
Registration Number
NCT03135262
Locations
🇺🇸

Mount Sinai Medical Center, New York, New York, United States

🇦🇺

Prince of Wales Hospital, Randwick, New South Wales, Australia

🇦🇺

Westmead Hospital, Westmead, New South Wales, Australia

and more 18 locations

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

First Posted Date
2017-04-13
Last Posted Date
2022-07-05
Lead Sponsor
University of California, San Diego
Target Recruit Count
4
Registration Number
NCT03113695
Locations
🇺🇸

University of California, San Diego, La Jolla, California, United States

Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)

First Posted Date
2017-03-22
Last Posted Date
2017-03-22
Lead Sponsor
Case Comprehensive Cancer Center
Registration Number
NCT03086395
© Copyright 2024. All Rights Reserved by MedPath